Author details

Full Name

Sridharan Gururangan

Affiliation

ORCID

Career Start Year

1990

Papers

137

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36808285	Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.	Neuro Oncol	2023
34668975	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry.	Neuro Oncol	2022
34994637	Upfront Adjuvant Immunotherapy of Replication Repair-Deficient Pediatric Glioblastoma With Chemoradiation-Sparing Approach.	JCO Precis Oncol	2021
33585982	Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1).	Acta Neuropathol	2021
33631016	A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.	Neuro Oncol	2021
33737307	Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials.	Clin Cancer Res	2021
34105033	Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes.	J Neurooncol	2021
34196917	Correction to: Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes.	J Neurooncol	2021
33502920	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma.	J Clin Oncol	2021
33405951	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).	J Clin Oncol	2021
33405376	A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042).	Pediatr Blood Cancer	2021
34678152	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies.	Cancer Cell	2021
31865440	Correction to: Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials.	Acta Neuropathol	2020
31802236	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials.	Acta Neuropathol	2020
31385990	Acute neurotoxicity following vincristine due to Charcot-Marie-Tooth disease in a young child with medulloblastoma.	Neuro-Oncology Practice	2019
30378286	Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumab.	Pediatric Blood and Cancer	2019
29793829	Best practices for the use of intracerebroventricular drug delivery devices.	Mol Genet Metab	2018
30019219	Heterogeneity within the PF-EPN-B ependymoma subgroup.	Acta Neuropathol	2018
29741745	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.	Neuro Oncol	2018
28089765	Intracerebroventricular Delivery as a Safe, Long-Term Route of Drug Administration.	Pediatr Neurol	2017
28825123	Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11).	Cancer Immunol Immunother	2017
28733147	Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex.	Journal of AAPOS	2017
28339824	A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.	Neuro Oncol	2017
27864705	The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial.	J Neurooncol	2017
26345283	Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation.	Br J Clin Pharmacol	2016
26976201	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.	Lancet Oncol	2016
27269943	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.	J Clin Oncol	2016
26279023	Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation.	Int J Radiat Oncol Biol Phys	2015
25930724	Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.	Childs Nerv Syst	2015
25665007	Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.	Nat Genet	2015
25814313	Corrigendum: Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.	Nat Genet	2015
25563815	Prognostic marker analysis in pediatric intracranial ependymomas.	Journal of Neuro-Oncology	2015
25940061	Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations.	Pediatr Blood Cancer	2015
26311248	Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.	J Neurooncol	2015
26169613	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.	J Clin Oncol	2015
24839957	CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity.	Acta Neuropathol	2014
24311632	Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.	Neuro Oncol	2014
24504791	Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.	Pediatr Blood Cancer	2014
24414535	Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.	Neuro Oncol	2014
23659599	Clinico-pathological description of three paediatric medulloblastoma cases with MLL2/3 gene mutations.	Neuropathol Appl Neurobiol	2014
24523595	Molecular variants and mutations in medulloblastoma.	Pharmacogenomics and Personalized Medicine	2014
23661102	Sluggish cognitive tempo in survivors of pediatric brain tumors.	J Neurooncol	2013
23002039	A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study.	Pediatr Blood Cancer	2013
24104527	Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).	Cancer	2013
23801675	Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium.		2013
24140199	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.	Lancet Oncol	2013
23592571	Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.	Neuro Oncol	2013
23169504	Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.	J Clin Oncol	2013
21938530	Phase II study of GleevecÂ® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.	Journal of Neuro-Oncology	2012
22790443	Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001).	J Neurooncol	2012